Author/Authors :
Samimi، Hilda نويسنده Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Samimi, Hilda , Azad-Fallah، Parviz نويسنده Department of Psychology, Faculty of Human Sciences, Tarbiat Modares University, Tehran, Iran Azad-Fallah, Parviz , Naderi Sohi، Alireza نويسنده Department of Nanotechnology and Tissue Engineering, Stem Cell Technology Research Center, Tehran, Iran. Naderi Sohi, Alireza , Tavakoli، Rezvan نويسنده Department of Molecular Biology and Genetic Engineering, Stem Cell Technology Research Center, Tehran, Iran. Tavakoli, Rezvan , Naderi، Mahmood نويسنده , , Soleimani، Masoud نويسنده , , Larijani، Bagher نويسنده , , Haghpanah، Vahid نويسنده Endocrine and Metabolism Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran. Haghpanah, Vahid
Abstract :
Personalized medicine is a set of diagnostic, prognostic and therapeutic approaches in which medical interventions are carried out based on individual patient characteristics. As life expectancy increases in developed and developing countries, the incidence of diseases such as cancer goes up among people in the community. Cancer is a disease that the response to treatment varies from one person to another and also it is costly for individuals, families, and society. Among thyroid cancers, anaplastic thyroid carcinoma (ATC) is the most aggressive, lethal and unresponsive form of the disease. Unfortunately, current drugs are not targetable, and therefore they have restricted role in ATC treatment. Consequently, mortality of this cancer, despite advances in the field of diagnosis and treatment, is one of the most important challenges in medicine. Cellular, molecular and genetic evidences play an important role in finding more effective diagnostic and therapeutic approaches. Review of these evidences confirms the application of personalized medicine in cancer treatment including ATC. A growing body of evidence has elucidated that cellular and molecular mechanisms of cancer would pave the way for defining new biomarkers for targeted therapy, taking into account individual differences. It should be noted that this approach requires further progress in the fields of basic sciences, pharmacogenetics and drug design. An overview of the most important aspects in individualized anaplastic thyroid cancer treatment will be discussed in this review.